Stock comparison
Harmony Biosciences Holdings
Lantheus Holdings
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HRMY
Harmony Biosciences Holdings
Market cap
$1.75B
Sector
Healthcare
LNTH
Lantheus Holdings
Market cap
$6.71B
Sector
Healthcare
Overall winner
Harmony Biosciences Holdings HRMY
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HRMY | LNTH | Winner |
|---|---|---|---|
| Warren Buffett | 67B | 61C | HRMY |
| Benjamin Graham | 60C | 60D | Tie |
| Philip Fisher | 75B | 61C | HRMY |
| Peter Lynch | 62C | 77B | LNTH |
| Joel Greenblatt | 28F | 41D | LNTH |
| Charlie Munger | 62C | 52D | HRMY |
| Terry Smith | 67B | 57D | HRMY |
Side-by-side metrics
| Metric | HRMY | LNTH |
|---|---|---|
| Market cap | $1.75B | $6.71B |
| P/E (TTM) | 11.8x | 22.3x |
| EV/EBIT | 6.4x | 18.6x |
| ROIC (TTM) | 12.5% | 10.75% |
| Gross margin | 76.55% | 60.48% |
| Net margin | 16.2% | 18.05% |
| Revenue CAGR 5y | 29.85% | 37.99% |
| EPS CAGR 5y | 46.45% | - |
| Debt / Equity | 0.2x | 0.0x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HRMY leads on
- EV/EBIT6.4xvs 18.6x+65%
- P/E (TTM)11.8xvs 22.3x+47%
- Gross margin76.55%vs 60.48%+21%
- ROIC (TTM)12.5%vs 10.75%+14%
LNTH leads on
- Debt / Equity0.0xvs 0.2x+100%
- Market cap$6.71Bvs $1.75B+74%
- Revenue CAGR 5y37.99%vs 29.85%+21%
- Net margin18.05%vs 16.2%+10%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.